1
|
Dong J, Wang S, Mao J, Wang Z, Zhao S, Ren Q, Kang J, Ye J, Xu X, Zhu Y, Zhang Q. Preparation of Dihydromyricetin-Loaded Self-Emulsifying Drug Delivery System and Its Anti-Alcoholism Effect. Pharmaceutics 2023; 15:2296. [PMID: 37765265 PMCID: PMC10535266 DOI: 10.3390/pharmaceutics15092296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Revised: 08/31/2023] [Accepted: 09/03/2023] [Indexed: 09/29/2023] Open
Abstract
Intraperitoneal injection of dihydromyricetin (DMY) has shown promising potential in the treatment of alcoholism. However, its therapeutic effect is limited due to its low solubility, poor stability, and high gut-liver first-pass metabolism, resulting in very low oral bioavailability. In this study, we developed a DMY-loaded self-emulsifying drug delivery system (DMY-SEDDS) to enhance the oral bioavailability and anti-alcoholism effect of DMY. DMY-SEDDS improved the oral absorption of DMY by facilitating lymphatic transport. The area under the concentration-time curve (AUC) of DMY in the DMY-SEDDS group was 4.13-fold higher than in the DMY suspension group. Furthermore, treatment with DMY-SEDDS significantly enhanced the activities of alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) in the liver of mice (p < 0.05). Interestingly, DMY-SEDDS also increased ADH activity in the stomach of mice with alcoholism (p < 0.01), thereby enhancing ethanol metabolism in the gastrointestinal tract and reducing ethanol absorption into the bloodstream. As a result, the blood alcohol concentration of mice with alcoholism was significantly decreased after DMY-SEDDS treatment (p < 0.01). In the acute alcoholism mice model, compared to saline treatment, DMY-SEDDS prolonged the onset of LORR (loss of righting reflex) (p < 0.05) and significantly shortened the duration of LORR (p < 0.01). Additionally, DMY-SEDDS treatment significantly reduced gastric injury in acute alcoholism mice. Collectively, these findings demonstrate the potential of DMY-SEDDS as a treatment in the treatment of alcoholism.
Collapse
Affiliation(s)
- Jianxia Dong
- Department of Medicinal Natural Products, West China School of Pharmacy, Sichuan University, Chengdu 610041, China; (J.D.); (S.W.)
- Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, China; (Z.W.); (J.K.)
| | - Shu Wang
- Department of Medicinal Natural Products, West China School of Pharmacy, Sichuan University, Chengdu 610041, China; (J.D.); (S.W.)
| | - Jiamin Mao
- Institute of Materia Medica, Structure-Specific Small Molecule Drugs Key Laboratory of Sichuan Provincial Universities, School of Pharmacy, Chengdu Medical College, Chengdu 610500, China; (S.Z.); (Q.R.); (J.Y.); (X.X.); (Y.Z.)
| | - Zhidan Wang
- Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, China; (Z.W.); (J.K.)
| | - Shiying Zhao
- Institute of Materia Medica, Structure-Specific Small Molecule Drugs Key Laboratory of Sichuan Provincial Universities, School of Pharmacy, Chengdu Medical College, Chengdu 610500, China; (S.Z.); (Q.R.); (J.Y.); (X.X.); (Y.Z.)
| | - Qiao Ren
- Institute of Materia Medica, Structure-Specific Small Molecule Drugs Key Laboratory of Sichuan Provincial Universities, School of Pharmacy, Chengdu Medical College, Chengdu 610500, China; (S.Z.); (Q.R.); (J.Y.); (X.X.); (Y.Z.)
| | - Jialing Kang
- Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, China; (Z.W.); (J.K.)
| | - Jing Ye
- Institute of Materia Medica, Structure-Specific Small Molecule Drugs Key Laboratory of Sichuan Provincial Universities, School of Pharmacy, Chengdu Medical College, Chengdu 610500, China; (S.Z.); (Q.R.); (J.Y.); (X.X.); (Y.Z.)
| | - Xiaohong Xu
- Institute of Materia Medica, Structure-Specific Small Molecule Drugs Key Laboratory of Sichuan Provincial Universities, School of Pharmacy, Chengdu Medical College, Chengdu 610500, China; (S.Z.); (Q.R.); (J.Y.); (X.X.); (Y.Z.)
| | - Yujin Zhu
- Institute of Materia Medica, Structure-Specific Small Molecule Drugs Key Laboratory of Sichuan Provincial Universities, School of Pharmacy, Chengdu Medical College, Chengdu 610500, China; (S.Z.); (Q.R.); (J.Y.); (X.X.); (Y.Z.)
| | - Quan Zhang
- Institute of Materia Medica, Structure-Specific Small Molecule Drugs Key Laboratory of Sichuan Provincial Universities, School of Pharmacy, Chengdu Medical College, Chengdu 610500, China; (S.Z.); (Q.R.); (J.Y.); (X.X.); (Y.Z.)
- Development and Regeneration Key Lab of Sichuan Province, Department of Pathology, Department of Anatomy and Histology and Embryology, Chengdu Medical College, Chengdu 610500, China
- Chengdu Nature’s Grace Biological Technology Co., Ltd., Chengdu 610213, China
| |
Collapse
|
2
|
Shiadeh SNR, Khodaverdi E, Maleki MF, Eisvand F, Boujaran H, Zarei H, Vosooghi R, Hadizadeh F, Kamali H. Lipid-liquid crystals for 2 months controlled risperidone release: In-vitro evaluation and pharmacokinetics in rabbits. Int J Pharm 2022; 618:121649. [PMID: 35278600 DOI: 10.1016/j.ijpharm.2022.121649] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2021] [Revised: 03/05/2022] [Accepted: 03/05/2022] [Indexed: 02/06/2023]
Abstract
In this study, a drug delivery system based on lipid liquid crystal (LLC) was developed for the long-term delivery of risperidone to improve psychological treatment. Optimal LLC formulation was achieved based on maximum release after 60 days with different ratios of phosphatidylcholine (PC) to sorbitol monooleate (PC: SMO), tween grade 80 (w/w %), and tocopherol acetate (TA) (w/w %) using the Box-Behnken method. In vitro and ex vivo studies, pharmacokinetics, and histopathological examination in rabbits were conducted to compare the optimal LLC with Risperdal CONSTA®. The optimum formulation containing the PC to SMO ratio of 58.6%, tween 0.82% w/w, and TA 3.6% w/w was selected because it had the highest drug release percentage (100%) during about two months. Polarized optical microscopy (POM) revealed HII mesophase with a 2-dimensional structure. Cell culture also revealed moderate cytotoxicity for LLC-risperidone. Pharmacokinetic data displayed that the optimal LLC created a more consistent drug serum level within 60 days, and histopathology results demonstrated slight to moderate damage in rabbits' organs. Furthermore, the accelerated stability test confirmed optimum stability for LLC and risperidone. This study confirmed the better pharmacokinetic potentials of SMO-based LLC systems compared with Risperdal CONSTA®, which would promote patient compliance and obviate the difficulties of additional oral therapy.
Collapse
Affiliation(s)
- Seyedeh Nesa Rezaeian Shiadeh
- Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Elham Khodaverdi
- Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Mahdi Faal Maleki
- Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Farhad Eisvand
- Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Hamidreza Boujaran
- Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Hassan Zarei
- Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Ramin Vosooghi
- Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Farzin Hadizadeh
- Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
| | - Hossein Kamali
- Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
| |
Collapse
|
3
|
Applications of innovative technologies to the delivery of antipsychotics. Drug Discov Today 2021; 27:401-421. [PMID: 34601123 DOI: 10.1016/j.drudis.2021.09.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Revised: 07/27/2021] [Accepted: 09/25/2021] [Indexed: 12/24/2022]
Abstract
Psychosis is a high-incidence pathology associated with a profound alteration in the perception of reality. The limitations of drugs available on the market have stimulated the search for alternative solutions to achieve effective antipsychotic therapies. In this review, we evaluate innovative formulations of antipsychotic drugs developed through the application of modern pharmaceutical technologies, including classes of micro and nanocarriers, such as lipid formulations, polymeric nanoparticles (NPs), solid dispersions, and cyclodextrins (CDs). We also consider alternative routes of administration to the oral and parenteral ones currently used. Improved solubility, stability of preparations, and pharmacokinetic (PK) and pharmacodynamic (PD) parameters confirm the potential of these new formulations in the treatment of psychotic disorders.
Collapse
|
4
|
Ryšánek P, Grus T, Šíma M, Slanař O. Lymphatic Transport of Drugs after Intestinal Absorption: Impact of Drug Formulation and Physicochemical Properties. Pharm Res 2020; 37:166. [PMID: 32770268 DOI: 10.1007/s11095-020-02858-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Accepted: 06/11/2020] [Indexed: 02/05/2023]
Abstract
PURPOSE To provide a comprehensive and up-to-date overview focusing on the extent of lymphatic transport of drugs following intestinal absorption and to summarize available data on the impact of molecular weight, lipophilicity, formulation and prandial state. METHODS Literature was searched for in vivo studies quantifying extent of lymphatic transport of drugs after enteral dosing. Pharmacokinetic data were extracted and summarized. Influence of molecular weight, log P, formulation and prandial state was analyzed using relative bioavailability via lymph (FRL) as the parameter for comparison. The methods and animal models used in the studies were also summarized. RESULTS Pharmacokinetic data on lymphatic transport were available for 103 drugs. Significantly higher FRL [median (IQR)] was observed in advanced lipid based formulations [54.4% (52.0)] and oil solutions [38.9% (60.8)] compared to simple formulations [2.0% (27.1)], p < 0.0001 and p = 0.004, respectively. Advanced lipid based formulations also provided substantial FRL in drugs with log P < 5, which was not observed in simple formulations and oil solutions. No relation was found between FRL and molecular weight. There were 10 distinct methods used for in vivo testing of lymphatic transport after intestinal absorption so far. CONCLUSION Advanced lipid based formulations provide superior ability to increase lymphatic absorption in drugs of various molecular weights and in drugs with moderate to low lipophilicity.
Collapse
Affiliation(s)
- Pavel Ryšánek
- Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
| | - Tomáš Grus
- Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Martin Šíma
- Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Ondřej Slanař
- Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| |
Collapse
|
5
|
Suresh A, Narayan R, Nayak UY. Recent advances in the development of asenapine formulations. Expert Opin Drug Deliv 2020; 17:1377-1393. [PMID: 32633149 DOI: 10.1080/17425247.2020.1792439] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
INTRODUCTION Asenapine maleate (AM) is an atypical antipsychotic agent, that has been widely prescribed for the management of schizoaffective disorders. However, the bioavailability of AM is extremely poor due to the extensive first-pass metabolism. With the advancement in pharmaceutical technologies, significant strides have been made to create novel formulations to address the bioavailability problem of AM. AREAS COVERED This review article provides an insight into all the formulation approaches undertaken by researchers to increase the bioavailability of AM encompassing the works utilizing ultrasound mediated transdermal delivery, nose to brain delivery, intestinal lymphatic system targeting, in situ implants, etc. All the patents associated with AM formulation have also been discussed and summarized. EXPERT OPINION Numerous studies have been carried out on AM formulations over the recent years, many of these studies have shown significant improvement in bioavailability. We have also mentioned the unexplored domains which can be exploited for further enhancing the bioavailability of AM. Nonetheless, most of these studies are still limited to the research laboratory level and face multiple hurdles before making into the market. Attaining controllability and reproducibility for the production of novel formulations is needed to enable its transition from bench to bedside.
Collapse
Affiliation(s)
- Akhil Suresh
- Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education , Manipal, India
| | - Reema Narayan
- Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education , Manipal, India
| | - Usha Y Nayak
- Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education , Manipal, India
| |
Collapse
|